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Hereditary hemolytic anemia encompasses a heterogeneous group of anemias
characterized by decreased red blood cell survival because of inherited membrane,
enzyme, or hemoglobin disorders. Affected red blood cells are more fragile, less
deformable, and more susceptible to shear stress and oxidative damage, and show
increased vesiculation. Red blood cells, as essentially all cells, constitutively release
phospholipid extracellular vesicles in vivo and in vitro in a process known as vesiculation.
These extracellular vesicles comprise a heterogeneous group of vesicles of different sizes
and intracellular origins. They are described in literature as exosomes if they originate
from multi-vesicular bodies, or as microvesicles when formed by a one-step budding
process directly from the plasma membrane. Extracellular vesicles contain a multitude
of bioactive molecules that are implicated in intercellular communication and in different
biological and pathophysiological processes. Mature red blood cells release in principle
only microvesicles. In hereditary hemolytic anemias, the underlying molecular defect
affects and determines red blood cell vesiculation, resulting in shedding microvesicles of
different compositions and concentrations. Despite extensive research into red blood cell
biochemistry and physiology, little is known about red cell deformability and vesiculation in
hereditary hemolytic anemias, and the associated pathophysiological role is incompletely
assessed. In this review, we discuss recent progress in understanding extracellular
vesicles biology, with focus on red blood cell vesiculation. Also, we review recent scientific
findings on the molecular defects of hereditary hemolytic anemias, and their correlation
with red blood cell deformability and vesiculation. Integrating bio-analytical findings on
abnormalities of red blood cells and their microvesicles will be critical for a better
understanding of the pathophysiology of hereditary hemolytic anemias.
Keywords: microvesicle, red blood cell, hemolytic anemia, membrane disorder, enzyme disorder,
hemoglobinopathy, erythrocyte
INTRODUCTION
Red blood cells (RBCs) are the most abundant cell type in human
blood and they function to transport oxygen (O2) from the lung
to all tissues and cells, and to transport carbon dioxide (CO2)
from tissues back to the lung. These functions dictate the unusual
capacity of RBCs to pass through all types of vessels, and even to
squeeze in capillaries of smaller diameters than RBCs themselves
(Mokken et al., 1992). Indeed, the molecular structures of normal
RBC membrane, cellular content, and energy machinery enable
such extraordinary deformability under the high shear forces of
blood flow (Svetina, 2012). Many patients with hereditary (inher-
ited) hemolytic anemias show aberrant RBC deformability due
to defects in one or more of RBC molecular components which
are crucial for the mechanical strength of RBCs as well as their
protection from oxidative stress (Hebbel, 1991; Gurbuz et al.,
2004; Da Costa et al., 2013). Non-immune hereditary hemolytic
anemias may be classified according to the underlying defects
into three major groups: membranopathies, enzymopathies, and
hemoglobinopathies (Dhaliwal et al., 2004).
Hereditary spherocytosis (HS) is the most common type
of hereditary hemolytic anemia. The estimated prevalence of
this membrane disorder is 1 in 5000 in the white population
of Northern Europe. Red blood cell glucose-6-phosphate-
dehydrogenase (G6PD) deficiency is the most common enzyme
disorder worldwide, affecting 420 million of the world popula-
tion. Less common is hemolytic anemia due to pyruvate kinase
(PK) deficiency with an estimated prevalence of 1 in 20,000
in the white population. Sickle cell anemia is the conspicuous
example of anemia due to a hemoglobinopathy. Its prevalence
is 1–5 in 10,000. For more prevalence data and other heredi-
tary hemolytic anemias, the ENERCA (European NEtwork for
Rare and Congenital Anaemias) website (www.enerca.org) and
the portal for rare diseases and orphan drugs (www.orpha.net)
are recommended.
Both in physiological and pathophysiological processes the
role of extracellular vesicles is increasingly appreciated. Most cells,
if not all, secrete extracellular vesicles, which comprise hetero-
geneous populations of vesicles of different compositions and
physicochemical properties. Considerable evidence is accumu-
lating showing the significance of extracellular vesicles as key
players for intercellular communication, in health and disease
(EL Andaloussi et al., 2013). Focusing on RBC vesiculation, both
in vivo or under blood storage conditions ex vivo mature RBCs
lose their membranes through shedding of microvesicles, a class
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of extracellular vesicles defined by the fact that they originate
from the plasma membrane (Greenwalt, 2006). In hereditary
hemolytic anemias, the molecular defects affect not only the RBC
but also their normal vesiculation pattern, resulting in the release
of circulating microvesicles which probably have a different com-
position compared to those derived from normal RBCs. Loss of
RBC membrane as microvesicles likely alters the cell’s surface
area-to-volume (S/V) ratio and RBC internal viscosity, and hence,
perturbs RBC deformability (Mohandas et al., 1980).
Alterations in RBC deformability can be measured using a
laser diffraction technique known as ektacytometry. Using this
technique, a thin layer of RBCs is sheared between two rotat-
ing surfaces, transforming RBCs from the discoid morphology
into the elliptical one. The laser beam is deflected by RBCs
to produce patterns from which RBC deformability is assessed
(Mohandas et al., 1980). Ektacytometry is a robust and easy-to-
perform technique, which can be routinely used to scan blood
samples to provide valuable information about abnormalities of
RBC deformability (Vent-Schmidt et al., 2013). Harnessing RBC
deformability and the emerging findings in extracellular vesicle
field may open up new avenues for understanding and diagnos-
ing rare, possibly neglected, diseases like hereditary hemolytic
anemias. This review provides brief insights into vesiculation,
RBC-derived vesicles and RBC deformability while emphasizing
their translational value for patients with hereditary hemolytic
anemias.
EXTRACELLULAR VESICLES AND THEIR PATHOPHYSIOLOGICAL
SIGNIFICANCE
Intercellular communication was believed to occur only via cell-
to-cell contact and/or secreted soluble factors. Within the last
three decades, there has been a paradigm shift in studying extra-
cellular vesicles as key mediators of intercellular communica-
tion. Extracellular vesicles are membranous lipid bilayer-vesicles
ubiquitously secreted by different cell types. Although there
are conserved vesicular components, the composition of extra-
cellular vesicles considerably varies according to the secreting
cells, the stimulus for their formation, in addition to the inter-
individual variability (Thery et al., 2009; Bastos-Amador et al.,
2012). Extracellular vesicles may be classified by their intracellu-
lar origins. For instance, a subtype of extracellular vesicles known
as exosomes originate from multi-vesicular bodies, and they are
secreted by a two-step process: inward budding of the plasma
membrane to form multivesicular bodies (MVBs) followed by
fusion of the MVBs with the plasma membrane. The second
subtype of extracellular vesicles is known as microvesicles or ecto-
somes, which are released by outward budding from the plasma
membrane (Thery et al., 2009).
Over the last two decades, extracellular vesicles have been
intensively studied after finding that they are more than cellu-
lar artifacts or clearance machineries of cellular junk. Stegrnayr
and Ronquist have published the first report on the functionality
of extracellular vesicles, showing that prostasomes could promote
human sperm motility (Stegmayr and Ronquist, 1982). However,
the biological functions of extracellular vesicles remained under-
estimated and unanalyzed until 1996 when Raposo et al. reported
that B lymphocytes-derived exosomes could stimulate adaptive
immune responses (Raposo et al., 1996). This work stimulated
the scientific community to investigate the biological functions of
extracellular vesicles, especially that these vesicles are secreted by
nearly all cell types, including stem cells, cancer cells, and cellular
components of blood. Beside their ubiquitous secretion, extracel-
lular vesicle formation and release probably occurs in a tightly
controlled manner and their bioactive cargo is selectively sorted
(Kriebardis et al., 2012).
Recently, advances in analytical techniques for nucleic acids
and proteomics enabled the identification of mRNAs, regulatory
miRNAs, and functional proteins loaded into/onto extracellular
vesicles. Such findings emphasize the pathophysiological signifi-
cance of extracellular vesicles, which may transfer these bioactive
payloads from one cell to another cell in many diseases (Raposo
and Stoorvogel, 2013). Pioneering work was performed by Valadi
et al. who demonstrated that exosomes could transfer functional
mRNA andmiRNAs between cells (Valadi et al., 2007). Later, Skog
et al. found that glioblastoma-derived microvesicles could pro-
mote tumor growth and angiogenesis via delivering angiogenic
and invasiveness factors to recipient cells in the tumor microenvi-
ronment (Skog et al., 2008). Moreover, a growing body of findings
shows the implications of extracellular vesicles that may fuel bac-
terial or viral virulence through transferring pathogenic factors,
either in pathogen-derived vesicles or in vesicles released from
pathogen hijacked-host cell vesiculation machineries (Silverman
and Reiner, 2011). Very recent work shows the importance of
circulating exosome-like vesicles released by Plasmodium falci-
parum-infected RBCs to the sexual stage of malarial infection
(Regev-Rudzki et al., 2013).
RED BLOOD CELL-DERIVED VESICLES
Red blood cells constitute 40% of the total blood volume and
they are one of the major vesicle-secreting cells in the circulating
blood (Xiong et al., 2012). Although the majority of circulating
microvesicles in healthy individuals are derived from platelets,
RBCs-derived microvesicles levels are elevated during the course
of some pathological conditions such as malaria and sickle cell
disease (Barteneva et al., 2013). Interestingly, extracellular vesicles
were first discovered as released by blood cellular components.
In 1967, extracellular vesicles were described by Wolf as prod-
ucts or dust that resulted from platelet membrane fragmentation
in human plasma (Wolf, 1967). Later, in 1983, two independent
groups reported the release of extracellular vesicles by exocytosis
of multivesicular endosomes during the maturation of reticulo-
cytes (Harding et al., 1983; Pan and Johnstone, 1983). Although
reticulocytes, or immature RBCs, secrete exosomes during the
remodeling process that accompanies their maturation, mature
RBCs are probably the only cells that do not secrete exosomes and
shed only microvesicles (de Vooght et al., 2013).
Red blood cell-derived microvesicles are submicron membra-
nous structures with a lipid bilayer rich in different phospholipids
and proteins, which are derived from parental RBCs. Their aver-
age size is approximately 100–200 nm.
During their 120-days life span, normal RBCs lose approxi-
mately 20% of their hemoglobin and membrane through vesic-
ulation (Werre et al., 2004). Red blood cell vesiculation can be
increased in vitro by increasing levels of intracellular calcium and
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by depleting endogenous ATP (Lutz et al., 1977; Bevers et al.,
1992). Under blood storage conditions, RBCs undergo structural
and morphological changes associated with ATP depletion and
oxidative damage of membrane lipids and proteins. Such changes,
known as storage lesions, eventually result in shedding microvesi-
cles and affect RBC survival after blood transfusion (Bosman
et al., 2008). These lesions are dependent on storage conditions,
storage length, and additives used in blood products (Veale et al.,
2011).
Red blood cell membrane components are key players in
microvesicle formation and release, and hence acknowledging
their roles may improve our understanding for RBC vesiculation.
The RBCmembrane is composed of a phospholipid bilayer, which
is penetrated by integral proteins (e.g., band 3, glycophorins A
and C, Rhesus-associated antigen), and tethered to the cytoskele-
ton network composed of α- and β-Spectrin and actin via protein
4.1R, protein 4.2, and ankyrin (Figure 1). The RBC membrane
and cytoskeleton proteins function to maintain the integrity of
plasma membrane, and also to confer deformability and mechan-
ical strength to RBCs (Mohandas and Gallagher, 2008). Besides,
several RBC membrane proteins have transport functions. For
instance, glucose transporter 1 (GLUT1) and aquaporin-1 con-
trols transport of glucose and water, respectively. Also, multiple
ion channels span the RBC membrane to regulate ion gradients
and the hydration state of RBCs (Thomas et al., 2011).
In the resting state, RBC membrane phospholipids are
asymmetrically distributed across the bilayer, meaning that the
neutral choline-containing phospholipids, like phosphatidyl-
choline and sphingomyelin, reside in the outer leaflet of the
RBC while the charged amino-containing phospholipids,
FIGURE 1 | Schematic representation of the red blood cell membrane.
The red blood cell membrane consists of a phospholipd bilayer that is
anchored to the 2-dimensional elastic network of skeletal proteins (mainly
spectrin) through transmembrane proteins (reproduced with permission
from Mohandas and Gallagher, 2008).
like phosphatidylserine (PS), phosphatidylinosirol, and
phosphatidyl-ethanolamine, reside in the inner leaflet of
the membrane (Zwaal and Schroit, 1997). Beside the RBC
cytoskeleton, the asymmetry of phospholipids across the RBC
membrane is crucial for maintaining RBC stability, deformability
and mechanical strength (Manno et al., 2002). The asymmetric
distribution of phospholipids is tightly controlled by three key
enzymes. The first is an ATP-dependent flippase which pumps
the amino-containing phospholipids from the outer leaflet to
the inner leaflet. The second is an ATP-dependent floppase
which controls the reverse transfer of the choline-containing
phospholipids from the inner leaflet to the outer leaflet, at slower
rate compared to flippases. The third enzyme is a divalent-cation
activated scramblase which controls the bi-directional transfer
of phospholipids down their concentration gradients to achieve
a more symmetrical distribution of phospholipids (Graham,
2004). Disruption of the plasma membrane phospholipid asym-
metry and externalization of PS are major steps in RBC vesicle
formation and release (Graham, 2004) (Figure 2).
High levels of intracellular Calcium activate scramblase and
inhibit flippase, and that results in a collapse of lipid asymme-
try and externalization of PS. The role of the floppase enzyme on
disturbing the membrane lipid asymmetry is not clear. However,
it may be involved in the rapid translocation of PS to the
external leaflet (Bevers et al., 1999; Graham, 2004). Meanwhile,
the increase of intracellular calcium also activates proteolytic
enzymes like calpain which breaks down the tethering points
between the membrane cytoskeleton and the plasma membrane,
facilitating the release of microvesicles (Morel et al., 2011).
However, Knowles et al. reported that RBC cytoskeleton did not
break down but retracted to the cell body during membrane
deformation under shear stress (Knowles et al., 1997). This find-
ing may explain the release of microvesicles, which are free from
cytoskeletal components. A simulation study for RBC membrane
demonstrated that the cell cytoskeleton may break and reform
in a dynamic manner and this may confer solid-to-fluid transi-
tion characteristics to the RBCmembrane under different stimuli
(Li et al., 2007). It is noteworthy that both the calcium-induced
phospholipid scrambling and the microvesicle release may occur
in two independent pathways. Bucki et al. found that stabiliz-
ing the phospholipid asymmetry by spermine did not inhibit
calcium-induced RBC vesiculation (Bucki et al., 1998). Yet the
exact underlying molecular mechanisms of RBC vesiculation are
far from being completely deciphered. It is not well known how
different stimuli, like calcium influx, amphiphiles, shear stress,
or ATP depletion, may induce shedding of microvesicles that
have different compositions. Furthermore, the selective sorting
of certain membrane components into microvesicles remains to
be understood (Knowles et al., 1997). Although the blood stor-
age remodeling process is presumed to be similar to RBC aging
in vivo, the role of cytoskeleton proteins in vesicle formation may
be different in vitro compared to in vivo (Bosman et al., 2010;
Canellini et al., 2012). Moreover, RBCs of different phenotypes
may shed microvesicles differently. For instance, although RBCs
in Scott syndrome, a rare hereditary bleeding disorder, have a
normal morphology and show no abnormalities in cytoskeleton
composition, they resist vesiculation upon stimulation with the
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FIGURE 2 | The plasma membrane response to cell stimulation.
Depicted is a general plasma membrane: a well-structured entity
characterized by a controlled transverse distribution of lipids and
different kinds of (transmembrane) proteins, and laterally organized
domains (rafts). Stimulation causes a redistribution of proteins,
structuration of rafts, externalization of PS, and release of
microparticles (reproduced with permission from Hugel et al.,
2005).
Calcium ionophore A23187 (Bevers et al., 1992). In a nutshell,
RBCs derived microvesicles are not always equal, and both RBC
phenotype and the triggering stimulus may determine the char-
acteristics of the released microvesicles.
Several physiological and pathophysiological functions of
RBC-derived microvesicles have been described. The main char-
acteristic of RBCs-derived microvesicles is the externalization of
the negatively charged PS, which has two main physiological
implications: (1) Promoting coagulation; (2) Acting as an “eat
me” signal for macrophages. The procoagulant activity of PS
relies on the catalytic activity of PS. PS acts as a binding sur-
face for prothrombinase and other coagulation factors, increasing
the transformation rate of prothrombin into thrombin, a major
coagulation molecule (Lentz, 2003). Although platelet-derived
microvesicles play an essential role in haemostasis regulation,
RBC-derived microvesicles could be equally important in cer-
tain pathological conditions like sickle cell disease (Tan and Lip,
2005; Weiss et al., 2011). Additionally, RBC-derived microvesicles
may promote thrombus formation in vivo via exposing tissue
factor, a key initiator of coagulation (Biro et al., 2003). Exposed
PS is a proposed “eat-me” signal for phagocytes to engulf PS-
exposing apoptotic cells. Such signaling provides a protection
from the toxic effects of apoptotic cells (Chaurio et al., 2009). The
same clearance mechanismmay occur for PS-exposingmicrovesi-
cles. It has been proposed that RBC vesiculation may serve as
a self-protection mechanism to prevent the early removal of
RBCs through removing the damaged components of the RBC
membrane. Thus, RBC-derived microvesicles “sacrifice” them-
selves; the reticuloendothelial system removes the PS-exposing
microvesicles instead of their parental RBCs, which probably
have restored lipid asymmetry after vesiculation (Willekens et al.,
2008).
Red blood cell-derived microvesicles may also be implicated
in immunomodulation, nitric oxide (NO)–redox homeosta-
sis, and in inflammatory reactions. These microvesicles may
have immunosuppressive activities by down-regulating the
macrophages that uptake them. Sadallah et al. showed that
RBCs-derived microvesicles were taken up by macrophages and
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this inhibited the release of tumor necrosis factor-α (TNF-α) and
interleukin 8 when these macrophage were exposed to zymosan
A and lipopolysaccharide (LPS), well-recognized as macrophage
stimulators (Sadallah et al., 2008). Such immune-suppressive
activities may have implications in the post-transfusion immune-
suppression and infections. On the other hand, Mantel et al.
found that RBCs infected with P. falciparum could release
microvesicles rich in host and parasites proteins and these
microvesicles possessed a potent stimulatory effect on cells of the
innate immune system (Mantel et al., 2013).
During blood storage, RBCs are subjected to storage lesions
which results in reduced integrity of the RBC membrane, associ-
ated with releasing the RBC oxy-hemoglobin content as cell-free
oxy-hemoglobin and vesicular oxy-hemoglobin. Both forms may
have enhanced scavenging activities for NO, a potent vasodilator.
Infusion of stored blood was shown to have a potent vaso-
constrictive effect associated with the degree of storage-related
hemolysis, potentially due to NO scavenging (Donadee et al.,
2011). Regarding the potential pro-inflammatory activities of
RBC-derived microvesicles, the vesicle membrane is a source
for amino-containing phospholipids, which are substrates of the
secretory phospholipase A2 (sPLA2) enzyme. Consumption of
vesicular phospholipids by sPLA2 may results in production of
lysophosphatidic acid, which is implicated in cell proliferation,
migration and inflammatory reactions (Fourcade et al., 1995).
HEREDITARY HEMOLYTIC ANEMIA: UNDERSTANDING THE
MOLECULAR BIOLOGY
Hereditary hemolytic anemias basically stem from intrinsic RBC
disorders. In this review we focus on this group of disorders which
can be due tomutations in genes that encode for: (1) a transmem-
brane/cytoskeleton protein; (2) an enzyme needed for ametabolic
reaction in RBCs; or (3) hemoglobin. The phenotypes of heredi-
tary hemolytic anemias range from being clinically asymptomatic
to severe life threatening conditions. In this section we discuss the
molecular bases of these disorders, and highlight their potential
relationships with RBC vesiculation.
RED BLOOD CELL MEMBRANE DISORDERS
Red blood cell membrane proteins control the mechanical
strength, the elastic deformability and the hydration state of
RBCs. Defect in one or more of these proteins may lead to
RBC membrane instability, increased membrane rigidity, and/or
aberrant hydration state of RBCs. These perturbations often are
associated with morphological changes and decreased life span of
the RBCs.
Hereditary spherocytosis
Hereditary spherocytosis (HS) is the most common inherited
hemolytic anemia due to a membrane defect. Inheritance is
mostly autosomal dominant and peripheral blood smears of HS
patients show spherocytes (sphere-shaped RBCs). However, sphe-
rocytic cells may also be seen in other acquired disorders like
autoimmune hemolytic anemias, thermal injuries, and venom
poisoning (Perrotta et al., 2008). The spherocytic morphology
of RBCs is due to loss of membrane surface area relative to
the cell volume. Most cases of HS are caused by deficiencies in
the membrane or cytoskeleton proteins ankyrin, band 3, pro-
tein 4.2, β-spectrin, or α-spectrin. The clinical severity of HS
varies according to the degree of spectrin loss, even if the primary
defect is not in the gene encoding spectrin (Chasis et al., 1988;
Eber et al., 1990). The aforementioned proteins are vital for the
vertical tethering of the RBC cytoskeleton network with themem-
brane lipid bilayer, and their loss results in reduced mechanical
strength and loss of membrane surface area through vesiculation.
Deficiency of one or more of the cytoskeleton components may
create an area of weakness in the membrane, facilitating RBC
vesiculation. Alternatively, loss of one of the integral proteins,
for instance band 3, may affect the membrane integrity. Thus,
the released microvesicles may differ from those released due to
deficiencies in cytoskeleton proteins. Indeed, in HS, RBC-derived
microvesicles were found to have different compositions based
on the underlying molecular defect. Reliene et al. showed that
microvesicles released from spectrin/ankyrin-deficient RBCs were
enriched in band 3 proteins. However, band 3-deficient RBCs did
not lose their few band 3 proteins. Loss of band 3 in microvesi-
cles released from spectrin/ankyrin-deficient RBCs reduced the
binding of membrane-bound immunoglobulin G (IgG) to band 3
clusters on RBCs, and hence reduced opsonization and immune-
mediated clearance of RBCs. In contrast, band 3-deficient RBCs
did not lose their band 3 molecules, which remained attached to
the cytoskeleton and clustered on the RBC membrane, and hence
were opsonized by IgG in vivo (Reliene et al., 2002).
Hereditary elliptocytosis
Hereditary elliptocytosis (HE) is another diverse group of inher-
ited RBC membrane disorders that are transmitted in an auto-
somal dominant manner with exception of pyropoikilocytosis
(HPP), a severe form of HE, which is generally transmitted in
an autosomal recessive manner. HE is characterized by ellipti-
cal RBCs (elliptocytes) on peripheral blood smears. However,
elliptocytes may also be seen in thalassemia and megaloblastic
anemias. The clinical manifestations of HE and HPP vary from
silent asymptotic conditions to a severe life threatening hemolytic
anemia (Nagel, 2006).
The hallmark of HE is the loss of mechanical stability of the
RBC membrane due to defects in membrane proteins main-
taining the lateral linkages of the RBC cytoskeleton. These
defects include quantitative and/or qualitative defects in proteins
α-spectrin, β-spectrin, and protein 4.1. The quantitative defects
result from reduced expression of genes encoding for normal pro-
teins. On the other hand, qualitative defects result in an alteration
in the protein structure that affects the protein interaction with
the adjacent proteins. HE RBCs are more susceptible to shear-
stress induced fragmentation which is associated with membrane
loss and progressive transformations of RBCs from the biconcave
morphology to the elliptical or oval one. Membrane loss is poten-
tially through shear-induced vesiculation, and such loss may be
involved in decreased deformability of HE RBCs. However, the
exact relationship between HE and vesiculation remains to be
studied (Wagner et al., 1986; Gallagher, 2004).
Hereditary stomatocytosis
Hereditary stomatocytosis (HSt) is a genetic disorder that com-
prises a heterogeneous group of syndromes, in which the RBC
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membrane is leaky to monovalent cations, showing increased
permeability to Na+ and K+. HSt is inherited in an autoso-
mal dominant manner. HSt RBCs can be seen as mouth-shaped
(stoma-) RBCs in peripheral blood smears. Like other RBCmem-
brane disorders, the phenotype of HSt patients may range from
being asymptomatic to suffering from a severe hemolytic anemia.
Membrane leakiness of monovalent cations alters the osmotic
pressure across the RBCs membrane, and hence affects RBC vol-
ume and cellular deformability. Such changes may decrease the
life span of defective RBCs and increase their splenic sequestra-
tion (Bruce, 2009; Da Costa et al., 2013).
HSt can generally be classified into two main phenotypes:
overhydrated HSt (OHSt) and dehydrated DHSt (also known as
xerocytosis). In OHSt, RBCs have high intracellular sodium con-
centration, which results in cell overhydration, reduction in the
mean cell hemoglobin concentration (MCHC), and transforma-
tion of RBCs into spherotic non-deformable cells. In xerocyto-
sis, increased membrane leakiness, in particular K+,results in a
reduction of total intracellular cation content. This induces RBC
dehydration associated with elevated MCHC, and thus perturbs
RBC deformability (Da Costa et al., 2013).
In OHSt, reduced levels of stomatin, a RBC membrane pro-
tein implicated in regulating K+/Na+transport across the mem-
brane, have previously been found. However, Stewart and Turner
reported that stomatin knockout mice did not have hemolytic
anemia, which may indicate that stomatin deficiency in OHSt
is a secondary event and not the primary underlying molecu-
lar defect of DHSt (Stewart and Turner, 1999). In agreement
with this, mutations in anion exchanger 1 (band 3) (Bruce et al.,
2005), the putative ammonium transporter Rhesus-associated
glycoprotein (RhAG) (Bruce, 2009), and GLUT1 (Flatt et al.,
2011) have recently been implicated in OHSt. Some patients
with HSt show normal levels of stomatin. It is worth mention-
ing that stomatin is a major lipid raft enriched in microvesicles
derived from normal RBCs during blood storage. Actin-stomatin
tethering may regulate the vertical association between the mem-
brane and cytoskeleton, and hence regulate vesiculation. Indeed,
Wilkinson et al. found that calcium-induced vesiculation is per-
turbed in stomatin-deficient RBCs of OHSt patients. By using
calcium and the ionophore A23187, microvesicles-derived from
stomatin-deficient RBCs were shown to be different in shape,
size, number and composition when compared to microvesicles
derived normal RBCs (Wilkinson et al., 2008). Yet, vesicula-
tion of stomatin-deficient RBCs under physiological conditions
remains to be studied. Some families affected by DHSt were
recently shown to have mutations in PIEZO1. PIEZO proteins
are pore forming subunits of mechanically activated cation chan-
nels (Andolfo et al., 2013). PIEZO1 mutations may be involved
in leakiness of RBC cations through the membrane (Albuisson
et al., 2013). It is not clear if RBC vesiculation is directly affected
by mutations in PIEZO1 or if it occurs as a secondary event due
to the perturbed deformability.
HEREDITARY HEMOLYTIC ANEMIA DUE TO RED BLOOD CELL ENZYME
DISORDERS
Mature RBCs lack nuclei andmitochondria, and they have limited
metabolic activities compared to other cells in the human body.
Nevertheless, their limited metabolic pathways are capable of
maintaining the RBC viability during its 120-days life span. These
pathways are also crucial for O2 binding and delivery, through
preserving hemoglobin in its functional form (Prchal and Gregg,
2005). Three main metabolic pathways exist in mature RBCs: (1)
The anaerobic glycolysis pathway (Embden–Meyerhof pathway);
(2) The pentose phosphate pathway; and (3) nucleotidemetabolic
pathways.
The Embden–Meyerhof pathway is the only source of
energy in RBCs. Under physiological conditions, the majority
of intracellular glucose is metabolized into pyruvate or lac-
tate by the anaerobic Embden–Meyerhof pathway to generate
Adenosine Triphosphate (ATP). The generated ATP is vital for
RBC biological functions, including glycolysis itself, and cellu-
lar structures. For instance, ATP is essential for kinase reac-
tions needed for cytoskeleton protein phosphorylation, which
is crucial for the integrity and deformability of RBCs (Betz
et al., 2009). Additionally, ATP molecules play a key role
in membrane phospholipids asymmetry by controlling ATP-
dependant phospholipids transporters (Daleke, 2008). In micro-
circulation, where O2tension is low, RBCs release not only
O2 but also ATP, whose vasodilating effects increase perfusion
flow (Sprague and Ellsworth, 2012). In addition to generating
ATP, Embden–Meyerhof pathway generates nicotinamide ade-
nine dinucleotide (NADH), an essential molecule for reducing
methemoglobin to hemoglobin. A shunt within the glycolysis
pathway known as the Rapoport-Luebering shunt is respon-
sible for the formation of 2,3-bisphosphoglycerate (2,3-BPG),
an important cofactor for modulating hemoglobin affinity to
O2for optimal O2 delivery to tissues (van Wijk and van Solinge,
2005).
The hexose monophosphate pathway consumes approximately
10% of the available glucose, under physiological conditions, to
maintain a high ratio of NADPH to NADP. NADPH is critical to
convert the oxidized form of glutathione (GSSG) to the reduced
form (GSH) and thus protecting critical structures like mem-
brane lipids and cytoskeleton proteins from oxidation. Under
high oxidative stress conditions, the pentose phosphate pathway
consumes more glucose to compensate for the depleted GSH
(McMullin, 1999). Mature RBCs lack the ability for de novo
synthesis of the adenine nucleotides needed for ATP produc-
tion. Instead, salvage pathways are used to recycle the existing
adenosine phosphate pool (Prchal and Gregg, 2005).
Multiple enzymes control the different metabolic pathways
in RBCs, some of which are key enzymes in the concerning
pathway. For example, glycolytic flux is mainly controlled by hex-
okinase, phosphofructokinase, glucose phosphate isomerase, and
PK. The hexose monophosphate shunt is controlled by glucose-
6-phosphate dehydrogenase. Pyrimidine 5′ nucleotidase is criti-
cally involved in the salvage pathway for nucleotide metabolism.
Inherited abnormalities in one of these enzymes, hereditary enzy-
mopathies, may result in chronic hemolytic anemias which vary
in severity according to the relative importance of the mutated
enzyme with regard to the functionality or the stability of this
enzyme. The most prevalent hereditary enzymopathies of RBCs
result from glucose-6-phosphate dehydrogenase (G6PD) defi-
ciency and PK deficiency (van Wijk and van Solinge, 2005).
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Glucose-6-phosphate dehydrogenase (G6PD) deficiency
G6PD deficiency is the most prevalent human enzyme deficiency,
affecting hundreds of millions of people around the world. The
disease is inherited as X-linked recessive trait. The majority of
G6PD mutations are missense mutations in G6PD gene located
on the X chromosome (band X q28). G6PD deficiency can be
categorized based on the severity into three main variants: (1)
Variants associated with episodic or acute hemolytic anemias; (2)
Variants associated with chronic hemolytic anemias; (3) Variants
associated with no clear risk of hemolysis (Gregg and Prchal,
2008).
G6PD activates the initial step of the hexose monophosphate
shunt, which is needed to maintain high levels of NADPH and,
consequently, GSH. Reduced glutathione is a sulfhydryl contain-
ing tripeptide acting intracellularly as a reducing agent. Reactive
Oxygen species (ROS) are by-products of normal physiologi-
cal intracellular reactions. However, ROS levels significantly rise
upon exposure to exogenous factors like ingestion of drugs with
high redox potentials, ingestion of fava beans, and during infec-
tions. Under normal conditions, oxidative damage is reversed by
adequate levels of GSH. However, G6PD deficient RBCs have low
levels of GSH, and they are more susceptible to damaging effects
of the accumulated ROS resulting in hemolysis (Cappellini and
Fiorelli, 2008). The exact molecular mechanisms of RBC hemoly-
sis in G6PD deficiency are unclear. The intracellular accumulation
of ROS may induce oxidation and clustering of membrane pro-
teins, precipitation of oxidized hemoglobin on the inner mem-
brane leaflet, and destabilization of the RBC membrane. Pantaleo
et al. found an increase in oxidation and phosphorylation of
band 3 proteins in G6PD-deficient RBCs, and that resulted in an
increase in RBC hemolysis as well as an increase in the release of
microvesicles containing hemichrome (Pantaleo et al., 2011).
Hemolytic episodes may stop despite the continuation of the
drug administration or persistence of infection. This is probably
due to the elimination of RBCs with lowest G6PD activity and,
hence, lowest GSH levels. G6PD enzyme activity decreases during
RBC aging; reticulocytes and younger RBCs usually have higher
levels of G6PD. Red blood cell morphology may change in G6PD
deficiency. Although in general RBC morphology is normal in
RBC enzymopathies, peripheral blood smears of G6PD defi-
ciency may display characteristic “bite cells” due to the oxidative
denaturation of hemoglobin (Cappellini and Fiorelli, 2008).
Pyruvate kinase (PK) deficiency
Pyruvate kinase (PK) deficiency is the most common glycolytic
enzyme defect and a relatively common cause of hereditary non-
spherocytic hemolytic anemias. Patients have variable degrees
of hemolysis, leading to mild compensated anemia, mod-
erate hemolysis that exacerbates during infection, to severe
transfusion-dependant chronic hemolytic anemia. The disease is
due to missense mutations in the PKLR gene, resulting in gen-
erating a defective isoenzyme of PK-R, the PK isozyme which is
specific to RBCs. PK deficiency is inherited in an autosomal reces-
sive manner. PK is a key enzyme in Embden–Meyerhof glycolysis;
it catalyses the transfer of a phosphoryl group from phospho-
enolpyruvate to ADP to generate ATP (van Wijk and van Solinge,
2005). Although ATP molecules are crucial for the stability of the
RBC membrane and for several enzymatic activities, the exact
underlying mechanism of RBC hemolysis in PK deficiency is
unclear. ATP deficiency is difficult to demonstrate, and other dis-
orders accompanied with ATP depletion do not show hemolysis.
Also, the selective splenic sequestration of young PK-deficient
RBCs and its relationship with RBCs structure remain to be
clarified (Zanella et al., 2005; Gregg and Prchal, 2008).
HEREDITARY HEMOLYTIC ANEMIAS DUE TO HEMOGLOBINOPATHIES
Hemoglobin is the main oxygen carrier in humans. It is a
tetrameric protein composed of two pairs of different globin
chains. Normal adult hemoglobin is mainly comprised of
Hemoglobin A (Hb A), which is composed of two α-globin
and two β-globin chains. Hemoglobin concentration (32–35 g
per 100mL of packed RBCs), the integrity and the solubility of
these hemoglobin molecules, and their oxygen affinity are crucial
factors for preserving the RBC’s main function, oxygen deliv-
ery. More than 1000 mutations in globin-encoding genes have
been found to affect hemoglobin synthesis, solubility, stability,
or oxygen affinity. Such inherited hemoglobin anomalies may
perturb the intracellular viscosity of RBCs and cell deforma-
bility, increasing the splenic sequestration of poorly deformable
cells. Moreover, these perturbations may trigger proteolytic reac-
tions, associated with ROS release, which may ultimately result in
hemolytic anemias (Kuypers, 2008; Steinberg et al., 2008).
Hemoglobin anomalies can be associated with quantitative
or qualitative abnormalities. Qualitative anomalies result from
structurally altered hemoglobin, which has perturbed physical
and/or chemical properties. Quantitative hemoglobinopathies are
due to a defective production of otherwise normal globin chains.
Examples of pathological conditions pertaining to the first group
are sickle cell anemia, hereditary met-hemoglobinemia, high
oxygen affinity polycythemia, and low oxygen affinity cyanosis.
Examples of pathological conditions related to the quantitative
anomalies are α- and β- thalassemias. By far the most preva-
lent and important conditions are sickle cell disease and the
thalassemia (Poyart and Wajcman, 1996).
Sickle cell disease
Sickle cell disease is a hereditary disorder in which patients
inherited a point mutation in the β-globin chain gene, encod-
ing for valine instead of glutamic acid at position 6. With few
exceptions, people with one sickle hemoglobin (HbS) gene are
asymptomatic (sickle cell trait). People who have homozygosity
for the mutation that causes HbS suffer from sickle cell disease.
Sickle hemoglobin (HbS) polymerizes and undergoes transfor-
mation from the soluble state to a highly viscous semisolid gel
under low oxygen tension conditions (Steinberg et al., 2008).
An outcome of hemoglobin polymerization is the change in the
morphology of RBCs, which in vitro become sickled, depend-
ing on the deoxygenation rate. HbS polymerization is different
under in vivo conditions. The amount of polymer existing in the
majority of cells in vivo is determined by the RBC hemoglobin
content, the physiological oxygen tension, and the delay time for
polymerization. Such factors affect the kinetics of polymerization
and influence our understanding for the disease pathophysiology
(Mozzarelli et al., 1987).
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The clinical manifestations of sickle cell disease are down-
stream complications related to the formation of hyperdense
RBCs (Lew and Bookchin, 2005) causing vaso occlusion. Main
clinical symptoms include hemolytic anemia, recurrent painful
episodes, chronic organ deterioration, particularly the spleen and
kidneys, and various acute complications. However, the severity
of sickle cell disease varies, and the genetics underlying this vari-
ability are far from being completely understood. One important
phenotypic modifier concerns the co-inheritance of HbS with
other mutant α- or β-thalassemia gene mutations (Poyart and
Wajcman, 1996).
HbS polymerization cause structural damage, thereby alter-
ing the red cell membrane. In addition, unstable HbS may cause
oxidative damage. Red blood cell membrane damages are asso-
ciated with PS externalization and band 3 clustering, which may
promote RBC opsonization, and consequently, RBC phagocyto-
sis (Waugh et al., 1986; de Jong et al., 2001). Additionally, these
membrane alterations may induce membrane surface area loss
through releasing microvesicles. The release of microvesicles from
sickled RBCs was first described by Allan et al. They reported that
reoxygenation of sickled RBCs could result in the release of spec-
trin free- and polymerized hemoglobin-containing microvesicles
(Allan et al., 1982). Others reported high levels of circulating
microvesicles in patients with sickle cell anemia (Westerman et al.,
2008).
Thalassemias
Thalassemias are a heterogeneous group of hereditary anemias
which result from reduced biosynthesis of one of the two globin
chains, α- or β- globin chain, that are needed to form the adult
hemoglobin tetramer, HbA. Individual disorders of thalassemias
are named according to the affected globin chain. For instance,
patients with α-thalassemia have absent or reduced α- globin
chains while patients with β-thalassemia have absent or reduced
β-globin chains (Steinberg et al., 2008). The α- and β-globin
chains in thalassemias are usually of normal structure.
Pathophysiological consequences of thalassemias arise from
the underproduction of hemoglobin and the intracellular accu-
mulation of excess globin subunits. The underproduction of
hemoglobin diminishes oxygen carrying capacity of surviving
RBCs. More importantly, the excess globin subunits probably
precipitate on the membrane inner leaflet, inducing damages in
the membrane cytoskeleton and decreasing the RBC deforma-
bility. Moreover, the rapid degradation of free globin chains in
RBC precursors may result in destruction of RBC precursors in
bone marrow associated with ineffective erythropoiesis (Poyart
and Wajcman, 1996; Steinberg et al., 2008).
THE LINKAGE BETWEEN HEREDITARY HEMOLYTIC ANEMIAS AND RED
BLOOD CELL-DERIVED MICROVESICLES
The relationship between hereditary hemolytic anemias and RBC
vesiculation is far from being completely deciphered. The diverse
molecular pathologies of hereditary hemolytic anemias proba-
bly play a key role in determining RBC deformability, fragility
and vesiculation. Thus, the phenotype and the levels of the cir-
culating RBC-derived microvesicles of each disorder are primar-
ily determined by the underlying molecular defects. Moreover,
therapeutic interventions, like splenectomy and pharmaceutical
compounds, may differently modify RBC vesiculation for each
disorder (Bütikofer et al., 1989; Westerman et al., 2008).
Red blood cell deformability probably shows a negative corre-
lation with RBC vesiculation. Such a correlation can be demon-
strated by a reduction in the extent of RBC deformability, which
is paralleled with an increase in microvesicle levels during blood
storage (Almizraq et al., 2013). However, others found that there
is a minimal change in RBC deformability during blood storage,
and such a finding could be explained by the parallel decline in
MCHC, which may compensate the effect of surface area loss
on RBC deformability (Cluitmans et al., 2012). In hereditary
membranopathies, like HS and HE, the instability of the RBC
membrane is most likely accompanied by a consequent mem-
brane loss through vesiculation, generating less deformable RBCs
which have less surface/volume ratio. By using a quantitative flow
cytometry method, Mullier et al. found that HS patients’ blood
contained higher levels of RBC-derived microvesicles compared
to healthy controls (Mullier et al., 2012). Regarding hereditary
hemoglobinopathies, unstable hemoglobin induces oxidation of
membrane proteins and lipids, deposition of hemoglobin on the
membrane, and changes in the intracellular viscosity, and that
all results in poorly deformable RBCs (Mokken et al., 1992). Red
blood cell tendency to shed microvesicles may reflect separation
of the membrane bilayer from the underlying skeleton by spicules
of polymerized deposited hemoglobin. For instance, in sickle
cell disease, a substantial percentage of cell-free hemoglobin is
encapsulated in RBC-derived microvesicles released during sick-
ling. Concerning hereditary RBC enzymopathies, the correlation
between RBC deformability and vesiculation is less clear than
other hereditary hemolytic disorders, probably due to two main
reasons; the genetic diversity of enzymopathies and the depen-
dency of membrane damage on the level of oxidative stress.
Johnson et al. reported increased deformability of G6PD-deficient
RBCs, which may be explained by the fact that RBCs in many
cases of glycolytic enzyme deficiency are foetal-like RBCs, which
are more deformable (Johnson et al., 1999). However, others
reported that G6PD-deficient RBCs were particularly susceptible
to oxidative stress-induced damage, and that results in a dramatic
reduction in RBC deformability (Gurbuz et al., 2004). Notably, it
is likely that patients may have different subpopulations of RBCs,
with different deformability, and that affects the overall deforma-
bility results (Mokken et al., 1992). The increased susceptibility
of RBCs to oxidative damage in hereditary enzymopathies may
cause microvesicle shedding. G6PD-deficient subjects may have
high levels of circulating RBC- and platelet-derived microvesicles
when compared to healthy controls, and microvesicle concen-
tration probably has a negative correlation with G6PD activity
(Nantakomol et al., 2012). However, vesiculation in other heredi-
tary enzymopathies remains to be understood.
Treatment modalities of hemolytic anemia, like splenectomy
and pharmaceutical compounds, may modify RBC deformabil-
ity and vesiculation. The anatomic structure of the spleen is
challenging for RBC metabolic machinery and deformability.
RBCs have to go through repeated deformations when passing
through both the capillary bed and the inter-endothelial slits of
the spleen, where RBCs are concentrated and their intracellular
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metabolism is stressed. Patients with hereditary hemolytic ane-
mias are likely to exhibit RBCs with morphological abnormalities
or metabolically distressed RBCs, which cannot withstand such
a splenic challenge. Thus, these abnormal RBCs are likely to
be sequestered by the spleen and subsequently phagocytosed
by splenic macrophages. Such splenic sequestration and ery-
throphagocytosis are responsible for the development of anemia
and splenomegaly (Mebius and Kraal, 2005). Notably, in sickle
cell disease the spleen is also one of the affected organs. During the
first decade of life the spleen is usually enlarged but due to vaso
occlusion events and infarction it undergoes progressive atrophy
leading to autosplenectomy (Pearson et al., 1979, 1985; Al Salem,
2011).
Splenectomy is indicated as a last option to treat the pro-
gressive increase in blood transfusion requirements due to the
splenomegaly-mediated hemolysis. In many cases of hereditary
hemolytic anemias, splenectomy may improve anemia, reduce
the rate of hemolysis, and eliminate symptoms of splenomegaly
(Reliene et al., 2002; Casale and Perrotta, 2011). However,
splenectomy is not a curative intervention, and sometimes
contraindicated due to post-surgery complications. Although
splenectomy may be beneficial for patients with HS or sickle
cell disease, it is contra-indicated for patients with HSt, who
may develop a hypercoagulable state after splenectomy result-
ing in thrombotic episodes or pulmonary hypertension (Stewart
et al., 1996; Stewart and Turner, 1999). Also splenectomised
β-thalassemia intermedia patients may develop venous throm-
boembolic complications like pulmonary embolism and deep
venous thrombosis (Westerman et al., 2008). The underlying
mechanisms of these thromboembolic events are not clear, and
the role of RBCs-derived microvesicles in these events remains ill-
defined. The transmembrane asymmetry of phospholipids and
PS externalization may be different among the different heredi-
tary hemolytic anemia, and these differences may play a crucial
role in the hypercoagulable state. HS and HE RBCs were shown
to have a normal transbilayer phospholipid asymmetry, whereas
RBCs of some stomatocytosis variants were shown to have altered
phospholipids asymmetry in addition to increased adherence to
endothelial cells (de Jong et al., 1999; Gallagher et al., 2003). It
is likely that splenectomy in stomatocytosis prolongs the circula-
tion of the PS-exposing RBCs, developing a hypercoagulable state.
Westerman et al. demonstrated that splenectomy may differently
affect the levels of PS-exposing microvesicles between sickle cell
anemia and thalassemia intermedia (Westerman et al., 2008). In
patients with thalassaemia intermedia, splenectomy was shown to
increase the levels of PS-exposingmicrovesicles, potentially due to
the diminished clearance of abnormal RBCs, which produce these
PS-exposing microvesicles. Although vesiculation may be facili-
tated by the spleen in healthy subjects, this would not explain the
post-splenectomy increase in RBC-derived microvesicles in tha-
lassaemia intermedia patients (Willekens et al., 2003; Westerman
et al., 2008).
The use of medications for therapeutic needs should be care-
fully considered in patients with hereditary hemolytic anemias.
Also, the diagnosis of such diseases and the analysis of RBCs-
derived microvesicles in hemolytic anemias should be carefully
performed with respect to the patient’s medical history. Exposure
of RBCs to pharmacologically active compounds, which have dif-
ferent physicochemical properties and mechanisms of actions,
may have different impacts on RBC morphology, deformability
and vesiculation. For instance, many drugs are amphiphilic in
nature, meaning that that they have hydrophobic and polar parts.
Based on the bilayer couple hypothesis, which hypothesizes
that RBC outer and inner leaflets respond differently to pertur-
bations, the morphological transformations of RBCs, and the
consecutive vesiculation, can be predicted from the nature of
the drugs interacting with RBCs (Sheetz and Singer, 1974). For
instance, anionic drugs, like indomethacine and phenyibutazone,
preferentially accumulate in the RBC outer leaflet and induce
RBC spiculation (echinocytosis) which results in membrane loss
through vesiculation. Such an interaction is electrostatically more
favorable due to the net negative charge of the inner mem-
brane leaflet. On the other hand, cationic drugs, like chlorpro-
mazine, primaquine and tetracaine, preferentially accumulate in
the inner leaflet and they induce a stomatocytic transforma-
tion of RBC morphology, resulting in inhibition of vesiculation
and/or endovesiculation (Bütikofer et al., 1987; Schreier et al.,
2000). It is not clear if the physical expansion of the inner or
the outer leaflet of the RBC membrane, based on the preferential
accumulation of amphiphilic drugs, is the sole event that affects
RBC transformations and vesiculation. Red blood cells possess
membrane-associated enzymes, which have different topological
arrangements/distribution across the cell membrane. For exam-
ples, ATPases, proteinases and acetylcholinesterase are known to
be confined to the membrane, whereas enzymes of glutathione
and glucose metabolism are found in the cytosol and associated
with the inner leaflet of the membrane (Schrier, 1977). Some of
these enzymes are involved in regulating RBC morphology, traf-
ficking of cations, and cell membrane rigidity. In addition to the
physical impacts, the intercalation of amphiphilic drugs may dif-
ferently affect the membrane-associated enzymes based on which
membrane leaflet is affected, and that may result in vectorial or
one-sided changes in the membrane enzymatic activities, leading
to differences in the RBC vesiculation behavior (Schrier, 1977;
Bütikofer et al., 1989; Schreier et al., 2000). Additionally, the
effects of amphiphilic drugs on RBC deformability and vesicu-
lation can be explained by the possible mechanisms of action of
antimicrobial peptides. An antimicrobial peptide, like gramicidin
D, has amphiphilic nature, and it may affect the cell membrane
integrity and ion permeability by two main possible mechanisms:
(1) the carpet-like mechanism; and (2) the barrel-stave mech-
anism. In the first mechanism, the peptide acts as a detergent
by lining on the cell membrane surface till reaching a critical
concentration at which the lipid bilayer is disrupted. In the lat-
ter mechanism, a membrane channel is formed, in which the
hydrophobic α- helical or β-sheets of the peptide interact with
the acyl chains of the membrane whereas the hydrophilic por-
tion lines the interior of the channel. Such a channel disrupts
the osmotic state of the cell by disrupting membrane permeabil-
ity (Schreier et al., 2000; Yeaman and Yount, 2003). Interestingly,
beside amphiphilic drugs, other pharmaceutical molecules seem
to intercalate with the RBC outer leaflet. For instance, Baerlocher
et al. found that Fluorouracil (5-FU), an anti-cancer drug,
could preferentially expand the outer leaflet of RBCs, inducing
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cell echinocytosis and shedding PS-exposing microvesicles. Such
microvesicles are potent stimulators of coagulation and may be
responsible for the thromboembolic complications that occur at
high therapeutic doses of 5-FU (Baerlocher et al., 1997). However,
others reported that the effects of 5-FU on RBCs may partially
be explained by the depletion of RBC ATP (Spasojevic et al.,
2005). Additionally, molecules that modulate calcium traffick-
ing may be of a therapeutic value for conditions associated with
RBCs of reduced deformability. Intracellular calcium plays crucial
roles in controlling membrane deformability and vesiculation. An
example of intracellular calcium modulators is zinc. Zinc ther-
apy in sickle cell anemia may reduce RBC sickling and improve
cellular deformability, potentially through inhibition of calmod-
ulin, an intracellular mediator of Calcium activities (Brewer et al.,
1977). Another example of a calcium antagonist is magnesium,
which may be administered intravenously to reduce the risk of
seizures in pregnant women with preeclampsia. Magnesium may
partially improve the impaired microcirculation in preeclampsia
by increasing RBC deformability through antagonizing the stim-
ulation of calcium pumps and reducing ATP depletion (Schauf
et al., 2004). An additional example is dipyridamole, an inhibitor
of platelet activation, which may enhance RBC deformability
by enhancing glucose uptake and boosting glycolysis, increasing
intracellular levels of ATP, and thus maintaining a more efficient
calcium pumping to the extracellular milieu (Sowemimo-Coker
et al., 1983; Saniabadi et al., 1992).
INTEGRATED BIO-ANALYTICAL FINDINGS: A NEED FOR PROFILING RED
BLOOD CELLS AND RED BLOOD CELL-DERIVED MICROVESICLES
Beside blood cell indices, current methodologies that are needed
for the basic understanding and clinical diagnosis of hereditary
hemolytic anemias encompass genetic analysis, protein analy-
sis, assessment of RBC deformability, flow cytometry, assays to
rule out immune-hemolytic anemia, and enzyme activity assays.
Rarity and diversity of hereditary hemolytic anemias, and our
incomplete understanding of RBC-derived microvesicles, which
can be considered as miniatures of the aberrant RBCs, repre-
sent a challenge for the scientific community. Overcoming such
a challenge is needed to have a better comprehension of the
diseases and to develop new therapeutics for each disease. An
approach to overcome these challenges is to combine and inte-
grate data from the several experimental platforms on RBCs and
their microvesicles to provide new insights into the molecular
interactions, cellular and vesicular (sub) phenotypes, and dis-
ease processes. Such profiling of hereditary hemolytic anemias
can be started by integrating data generated by robust methods
like ektacytometry, flow cytometry, nanoparticle characterization
and proteomics.
Cytometry
Ektacytometry is defined in the dictionary of cell and molecular
biology as a “Method in which cells (usually RBCs) are exposed to
increasing shear-stress and the laser diffraction pattern through
the suspension is recorded; it goes from circular to elliptical as
shear increases. From these measurements, a deformability index
for the cells can be derived.” (Lackie, 2007). Determination of
deformability index (DI), also known as elongation index (EI),
is indicative to cell membrane rigidity. A variety of ektacytometry
is the osmotic gradient ektacytometry, in which RBCs are sus-
pended in solutions of polyvinylpyrrolidone (PVP) of varied
tonicity and the DI is determined as a continuous function of
the suspending medium osmolality at a constant shear rate. By
keeping in mind that RBC membrane is highly permeable to
water, any change in the osmolality of the suspension medium
results in a change in the hydration state of RBCs (Johnson
and Ravindranath, 1996). Red blood cell deformability is deter-
mined by RBC internal viscosity, membrane surface to volume
ratio, and membrane rigidity. Alterations of one or more of these
three determinants can be detected by interpreting changes in
the osmotic gradient deformability profile. Since the underlying
molecular defects of hereditary hemolytic anemias are different,
a number of these anemias can be rapidly diagnosed by their
distinctive osmotic gradient deformability profile (Clark et al.,
1983; Johnson and Ravindranath, 1996; Da Costa et al., 2013).
Combining these profiles with other haemorheological param-
eters like the aggregation behavior of RBCs may be of added
value in further profiling of hereditary hemolytic anemias. An
example of such a hybrid technique is the commercially available
instrument called LORCA (Laser-assisted Optical Rotational Cell
Analyzer) (Hardeman et al., 2001).
Flow cytometry is a simple, reproducible, and high through-
put method that can be used for qualitative and quantitative
immunophenotyping of RBCs. The availability of a wide array
of fluorescently labeled antibodies can be utilized to detect sev-
eral RBC surface and cytoplasmic antigens that may vary among
hereditary hemolytic anemias. Additionally, laser scattering at dif-
ferent angles can distinguish differences in cell size and internal
complexity (Brown and Wittwer, 2000; Davis, 2001). An auto-
mated hematology analyser like the Abbott cell-dyn Sapphire can
also be modified to detect morphological abnormalities of the
analyzed RBCs (Kim et al., 2003).
Nanoparticle characterization
The submicron size of microvesicles poses several challenges for
analysis. To characterize their biological characteristics, such as
surface proteins, tools that have originally been developed for
cells are usually employed, like flow cytometry. The limited scat-
tering properties of nanosized particles make flow cytometry of
microvesicles not straightforward.
This is primarily caused by the lack of standardized assay pro-
tocols in addition to the heterogeneity in size (where the majority
of the population usually is well below the detection threshold)
and composition of microvesicles (Shah et al., 2008; Sustar et al.,
2011). Another challenging factor is that the clearance of RBCs-
microvesicles seems to be a very efficient process (Willekens et al.,
2005). Thus, it is not clear if the flow cytometry quantification
of these microvesicles represent their constant circulating levels
in vivo or that these levels are highly variable in time. Thus, there
is a need to standardize flow cytometry protocols and to profile
the phenotypes of RBCs and their microvesicles in the different
hemolytic anemias.
There are two main approaches that may be employed
in analysing RBC-derived microvesicles: (1) selection of
microvesicles based on a size criterion followed by analysis of
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the fluorescent signals of events limited to this preselected size,
or (2) initial selection is based on the fluorescent signals then
limiting the analysis by scatter gating to these signals (Xiong
et al., 2012). Among the generally investigated antigens of RBCs
and RBC-derived microvesicles are glycophorin A, PS, and
band 3. Glycophorin A is expressed on the vast majority of
RBC-derived microvesicles, and it is considered as a universal
marker to distinguish RBC-derived microvesicles from those
of other cell lineages (Pattanapanyasat et al., 2004). Vesicle PS
can be labeled by Annexing V. However, it is not clear if all
RBCs-derived microvesicles expose PS (Barteneva et al., 2013).
Flow cytometry can also be used to quantify the transmembrane
band 3 proteins by labeling with the dye eosin-5′ maleimide
(EMA). EMA staining is frequently used in the diagnosis of
HS (Girodon et al., 2008). As aforementioned, the molecular
defects in HS are heterogeneous; a common feature of HS RBCs
appears to be a weakening of the tethering points associated
with band 3, and that facilitates RBC vesiculation and losing
band 3 from the RBC membrane into the released microvesicle.
Indeed, Stoya et al. and Knowles et al. reported that the EMA
fluorescence signal was reduced in HS RBCs and after heat- or
shear-induced vesiculation of normal RBCs, and the released
microvesicles showed membrane associated-EMA labeled band
3 proteins (Knowles et al., 1997; Stoya et al., 1997). Although the
EMA test is highly sensitive, it is not without drawbacks. EMA
binds covalently to the Lys430 on the extracellular loop of band
3 protein but it may also bind to sulfhydryl groups expressed
by Rh, RhAg and CD47. Moreover, some mutants of band 3
fail to bind to the dye EMA. The use of EMA test is also less
effective in diagnosis of HS due to ankyrin defects (Girodon
et al., 2008).
From the pharmaceutical technology field a number of tech-
niques are available to characterize physicochemical properties of
vesicles, such as size and surface charge. These can be measured
by a variety of techniques such as dynamic light scattering, elec-
tron microscopy, tunable resistive pulse sensing, or nanoparticle
tracking analysis. These techniques, however, have difficulties in
assessing the biological heterogeneity of samples. As an exam-
ple, nanoparticle tracking analysis studies the brownian motion
of microvesicles, which can be tracked through the scattered light
after laser illumination. Since the antigen number on the surface
of nanosized vesicles is relatively small, it is difficult to extract
biological information on surface markers as the absolute signal
remains low.
The proteome of red blood cells and their microvesicles
Mature RBCs are anucleate cells with few intracellular structures
and no capability to synthesize new proteins. Thus, their pro-
teome is less complex compared to other cell types. This fact,
along with the comprehension of RBC physiology, opens up an
opportunity to use proteomic techniques for a better under-
standing of hereditary hemolytic anemias. Mass spectrometry
(MS) is a powerful, automated and high throughput tool, which
enables us to analyse the proteome of RBCs in health and dis-
ease. Such a comparative proteomic analysis can provide us with
considerable insights into disease-related alterations and severity,
potential diagnostic markers, potential therapeutic targets, and
drug-induced changes (Prudent et al., 2011). Such studies may
improve our understanding of the underlying complex patho-
physiology of hereditary hemolytic anemias like sickle cell disease,
HS andHE (Kakhniashvili et al., 2005;Margetis et al., 2007; Pasini
et al., 2010; Yuditskaya et al., 2010). Despite advances in MS,
proteomic studies of RBCs in hereditary hemolytic anemias are
limited.
There is a growing interest in using proteomic technologies
for high throughput protein profiling of extracellular vesicles.
Such an interest is driven by new findings pointing to the crucial
roles in intercellular communications and other pathophysio-
logical processes. With respect to RBC-derived microvesicles,
little is known about their protein cargo (Simpson et al., 2009).
Proteomic data are mainly available on microvesicles derived
from normal RBCs during storage under blood bank conditions
(Tissot et al., 2013). Bosman et al., in a series of proteomic
studies, investigated the effect of storage conditions and RBC
ageing on RBC vesiculation (Bosman et al., 2008, 2010, 2012;
Willekens et al., 2008). By comparing the proteome of RBC-
derived microvesicles with the proteome of the parental RBC
membrane, the Bosman group hypothesized that RBCs-derived
microvesicles and vesiculation may be a means to selectively
remove senescent cell antigens and other molecules to postpone
the premature elimination of RBCs from the circulation. In the
context of hereditary hemolytic anemias, Chaichompoo et al.
showed that the levels of 29 proteins of microvesicles derived from
β-thalassemia/hemoglobinE patients were significantly altered
when compared to controls. These proteins included peroxire-
doxin 6, apolipoprotein E, cyclophilin A and heat shock protein
90, and they were primarily involved in the regulation of RBC
redox reactions, phospholipid turnover, and blood coagulation
(Chaichompoo et al., 2012).
CONCLUDING REMARKS
Red blood cells-derived microvesicles, once thought of as cell
debris, now seem to have important roles in regulating blood
homeostasis and modulating immune response and other patho-
physiological processes. Red blood cell microvesiculation is a
tightly controlled process and sorting of bioactive molecules into
microvesicles occurs in a selective manner. The molecular defects
of hereditary hemolytic anemia are diverse, and they potentially
affect RBC vesiculation. Microvesicles released in the different
hereditary hemolytic anemias are potentially unequal and may
have different biological effects. As the exact role of red cell
derived miscrovesicles in many of the hemolytic anemias is cur-
rently unknown and unexplored this opens up a whole area of
exciting research in the coming period of time. Understanding
the molecular bases of hereditary hemolytic anemias, and their
impact on RBCs deformability and microvesiculation, can pro-
vide new insights into the pathophysiology of these anemias
and may lead to the discovery of new diagnostic markers and
therapeutic molecules.
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